Enduring Material

• Describe the known basic science, pathophysiology and psychosocial impact of psoriatic arthritis and be able to appropriately diagnose PsA
• Employ appropriate strategies to identify risk factors for and treat comorbidities and complex cases associated with psoriatic arthritis
• Implement the newly released American College of Rheumatology-National Psoriasis Foundation guideline for the treatment of psoriatic arthritis including treat to target goals.
• Exhibit knowledge of the indications, recommended dosages, efficacy, monitoring and side effects for current psoriatic disease therapies
• Develop strategies to approach shared psoriatic disease treatment options using collaborative care and appropriate referral

• Evan Siegel, MD - Georgetown University School of Medicine
• Elaine Husni, MD - Cleveland Clinic
• Joseph Merola, MD - Brigham & Women's Hospital

• The National Psoriasis Foundation designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Shared Management Roundtable

Elaine Husni, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Amgen - Advisory Committee Member - Relationship Has Not Ended
• BMS - Advisory Committee Member - Relationship Has Not Ended
• Lilly - Advisory Committee Member - Relationship Has Not Ended
• Novartis - Advisory Committee Member - Relationship Has Not Ended
• Janssen - Advisory Committee Member - Relationship Has Not Ended
• UCB - Advisory Committee Member - Relationship Has Not Ended
• PASE - questionnaire royalties - Relationship Has Not Ended

Joseph Merola, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Abbvie, Amgen, Bayer, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi-Regeneron, Biogen, Pfizer, and BMS - Consulting - Relationship Has Not Ended
• Dermavant, UCB, LEO Pharma, Sanofi, Lilly - Investigator - Relationship Has Not Ended

Evan Siegel, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Eli Lilly & Company - Advisory Committee Member - Relationship Has Not Ended
• Eli Lilly & Company - Speaking - Relationship Has Not Ended
• AbbVie - Advisory Committee Member - Relationship Has Not Ended
• AbbVie - Speaking - Relationship Has Not Ended
• Horizon - Speaking - Relationship Has Not Ended
• UCB - Advisory Committee Member - Relationship Has Not Ended
• UCB - Speaking - Relationship Has Not Ended
• BMS - Advisory Committee Member - Relationship Has Not Ended

This activity is supported by an educational grant from Pfizer

• The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

0 %

100 %

1/11/2022